E-ISSN: 2587-0831 ISSN: 2587-0831
The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome
PDF
Cite
Share
Request
Original Article
VOLUME: 14 ISSUE: 4
P: 211-217
October 2018

The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome

Eur J Breast Health 2018;14(4):211-217
DOI: 10.5152/ejbh.2018.4170
Burcu Çakar 1
Zeki Sürmeli 2
Pınar Gürsoy Öner 3
Elif Sıla Yelim 4
Bülent Karabulut 1
Ruchan Uslu 1
1. Division of Medical Oncology, Tülay Aktaş Oncology Hospital, Ege University School of Medicine, İzmir, Turkey
2. Division of Medical Oncology, Medical Park Hospital, Ankara,Turkey
3. Division of Medical Oncology, Suat Seren Chest Hospital, İzmir, Turkey
4. Division of Internal Medicine, Ege University School of Medicine, İzmir, Turkey
No information available.
No information available
Received Date: 27.04.2018
Accepted Date: 20.06.2018
PDF
Cite
Share
Request

ABSTRACT

Objective:

Inflammatory breast cancer (IBC) has an unfavourable prognosis despite the advances made in the treatment of breast cancer. Our study aimed to define immunohistochemistry-based surrogate subtype distribution to determine whether the breast cancer subtype accompanied survival outcome differences in IBC.

Materials and Methods:

Medical records of female breast cancer patients with non-metastatic inflammatory breast cancer admitted to our clinic between March 2000 and December 2015 were retrospectively reviewed. Patient demographics, clinical and pathological feature of the primary tumour, adjuvant treatment options and survival data were analysed. Intrinsic breast cancer subtypes were defined according to ER, PR, HER-2 and ki-67 status.

Results:

We identified 129 non-metastatic inflammatory breast cancer patients. Median follow-up was 73 months. 10 (7.7%) were luminal A-like, 67 (51.9%) were luminal B-like, 37 (28.6%) were HER-2 positive, and 15 (11.6%) were triple negative (TNBC) by immunohistochemistry. There were no statistically significant differences between subtypes in terms of histological type, grade, tumour size and lymph node status. Median diseasefree survival was 47 months (95% confidence interval [CI] 29.2-82.6) and median overall survival was 75 months (95% CI 64.7-90.8). Triple negative breast cancer showed poorer outcome than other subgroups. Presence of TNBC disease was associated with poorer outcome compared to luminal A (HR: 0.19, 95% CI 0.04-0.92, p: 0.039), luminal B (HR: 0.34, 95% CI 0.15-0.74, p: 0.007) and HER-2 positive subgroups (HR: 0.40, 95% CI 0.17-0.94, p:0.037). Luminal A patients had a trend to have a better overall survival which did not reach to a statistical significant difference.

Conclusion:

Our study put forth that IBC have a poor prognosis irrespective of breast cancer surrogate subtype distribution. Luminal A, the most frequent subtype of breast cancer was the least common in our IBC patient group. TNBC had the worst outcome when compared to other breast cancer subtypes.